Sanofi and Re­gen­eron clear the fin­ish line in an in­flam­ma­to­ry esoph­a­gus dis­ease, leav­ing Take­da in the dust

With atopic der­mati­tis ri­vals breath­ing down Dupix­ent’s neck, Sanofi and Re­gen­eron on Fri­day se­cured a first win in new ter­ri­to­ry in what Sanofi’s head of im­munol­o­gy and in­flam­ma­tion Naimish Pa­tel called the fastest ap­proval he’s ever seen.

The FDA ap­proved Dupix­ent on Fri­day to treat pa­tients 12 years and old­er with eosinophilic esophagi­tis (EoE), an in­flam­ma­to­ry con­di­tion that caus­es swelling and scar­ring of the esoph­a­gus. The ap­proval came just a cou­ple months af­ter reg­u­la­tors grant­ed Dupix­ent pri­or­i­ty re­view, and months ahead of its PDU­FA date on Aug. 3.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER